• head_banner_01

Leading Manufacturer for Furfuryl Acetate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

In order to best meet client's needs, all of our operations are strictly performed in line with our motto "High Quality, Competitive Price, Fast Service" for Bromide Lithium, Nopyl Acetate, Olaparib, Our main objectives are to provide our customers worldwide with good quality, competitive price, satisfied delivery and excellent services.
Leading Manufacturer for Furfuryl Acetate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex Detail:

Product Detail

Name  Eptifibatide
CAS number  188627-80-7
Molecular formula  C35H49N11O9S2
Molecular weight  831.96
EINECS Number  641-366-7
Density  1.60±0.1 g/cm3(Predicted)
Storage conditions  Sealed in dry, store in freezer, under -15°C

Synonyms

Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;Eptifibatide;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDEBRIDGE,MPA1-CYS6).

Platelet Glycoprotein Antagonist

Etifibatide (integrilin) ​​is a novel polypeptide platelet glycoprotein IIb/IIIa receptor antagonist, which inhibits platelet aggregation and thrombosis by inhibiting the last common pathway of platelet aggregation. Compared with the monoclonal antibody abciximab, eptifibatide has a stronger, more directional and specific binding to GPIIb/IIIa due to the existence of a single conservative amino acid substitution—lysine to replace arginine. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome. Platelet glycoprotein IIb/IIIa receptor antagonist drugs have been developed a lot, and currently there are 3 kinds of preparations that can be used in clinical internationally, abciximab, eptifibatide and tirofiban. ). There is little experience in the use of platelet glycoprotein GPIIb/IIIa receptor antagonists in China, and the available drugs are also very limited. Only one drug, tirofiban hydrochloride, is on the market. Therefore, a new platelet glycoprotein IIb was developed. /IIIa receptor antagonists are imperative. Domestic eptifibatide is an imitation product produced by Chengdu Sino Biological Products Co., Ltd.

Classification

Classification of Antiplatelet Aggregation Drugs

Antiplatelet aggregation drugs can be roughly divided into three categories: 1. Cyclooxygenase-1 (COX-1) inhibitors, such as aspirin. 2. Inhibit platelet aggregation induced by adenosine diphosphate (ADP), such as clopidogrel, prasugrel, cangrelor, ticagrelor, etc. 3. Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists, such as abciximab, eptifibatide, tirofiban, etc. In addition, there are prostaglandin EP3 receptor inhibitors, newly synthesized chemical components and effective extracts from traditional Chinese medicine.


Product detail pictures:

Leading Manufacturer for Furfuryl Acetate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex detail pictures

Leading Manufacturer for Furfuryl Acetate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex detail pictures


Related Product Guide:

We strive for excellence, services the customers", hopes to be the top cooperation team and dominator business for personnel, suppliers and prospects, realizes benefit share and continual promotion for Leading Manufacturer for Furfuryl Acetate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex , The product will supply to all over the world, such as: Czech republic, Serbia, Palestine, Our company will continue to adhere to the " superior quality, reputable, the user first " principle wholeheartedly. We warmly welcome friends from all walks of life to visit and give guidance, work together and create a brilliant future!
  • Managers are visionary, they have the idea of "mutual benefits, continuous improvement and innovation", we have a pleasant conversation and Cooperation.
    5 Stars By Donna from Turkey - 2018.10.01 14:14
    In general, we are satisfied with all aspects, cheap, high-quality, fast delivery and good procuct style, we will have follow-up cooperation!
    5 Stars By Austin Helman from Pakistan - 2017.05.21 12:31
    Write your message here and send it to us